References
- Shin DW, Moon SH, Kim JH. Diagnosis of cholangiocarcinoma. Diagnostics (Basel). 2023; 13:233.
- Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39(Suppl 1):7–18.
- Lalani T, Couto CA, Rosen MP, Baker ME, Blake MA, Cash BD, et al. ACR appropriateness criteria jaundice. J Am Coll Radiol. 2013; 10:402–9.
- Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol. 2009; 15:5976–82.
- Pabst KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, Steiger K, Bartel T, et al. Superior tumor detection for 68Ga-FAPI-46 versus 18F-FDG PET/CT and conventional CT in patients with cholangiocarcinoma. J Nucl Med. 2023; 64:1049–55.
- Labib PL, Goodchild G, Pereira SP. Molecular Pathogenesis of cholangiocarcinoma. BMC Cancer. 2019; 19:185. doi: 10.1186/s12885-019-5391-0
- Lu S, Li J. Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo. Asian Biomed (Res Rev News). 2024; 18:61–8.
- Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022; 27:100737. doi: 10.1016/j.aohep.2022.100737